Regulations and Regulatory Advocacy
The Department of Health and Human Services and other federal agencies today issued a final rule delaying the general compliance date for 2018 requirements under the Common Rule to Jan. 21, 2019, giving covered entities six additional months to implement the requirements.
In comments submitted yesterday, AHA strongly urged the Centers for Medicare & Medicaid Services to withdraw a proposed rule that would exempt states with high Medicaid managed care enrollment or that propose 鈥渘ominal鈥 rate reductions from requirements to assess whether their Medicaid fee-for-鈥
On April 24, the Centers for Medicare & Medicaid Services published the FY 2019 proposed rule for the long-term care hospital prospective payment system. The AHA Regulatory Advisory below offers a detailed summary of the proposed rule.
On May 8, the Centers for Medicare & Medicaid Services published the FY 2019 proposed rule for the skilled nursing facility prospective payment system. The AHA Regulatory Advisory offers a detailed summary of the proposed rule.
AHA's comment on the CMS proposed rule to amend requirements that states assess their Medicaid fee-for-service provider payments to determine if they are sufficient to ensure beneficiary access to covered services.
AHA comments to HRSA regarding proposed rule that would further delay the effective date for implementing final regulations regarding the 340B Drug Pricing Program ceiling price and drug manufacturers鈥 civil monetary penalties (CMPs) for violations of the ceiling price.
The Centers for Medicare & Medicaid Services today released the agency鈥檚 strategy to promote high-quality health care for all rural Americans, address the unique economics of providing rural health care, and bring a rural focus to CMS health care delivery and payment reforms.
The Department of Health and Human Services today proposed delaying to July 1, 2019 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers.
The undersigned groups thank the Drug Enforcement Administration (DEA) for the opportunity to comment on its proposed rule regarding controlled substances quotas. Although we support DEA鈥檚 efforts to combat diversion, we are concerned that the proposed rule is focused on diversion to the exclusion鈥
We concur with the DEA that setting quotas for the production of opioid medications can be an effective step in 鈥減reventing the accumulation of controlled substances in amounts exceeding legitimate need,鈥 and therefore reduce the chance that these powerful medications will be diverted for non-鈥